| Identification | Back Directory | [Name]
CDDO-3-P-Im | [CAS]
1883650-96-1 | [Synonyms]
CPD1599
CPDB1599
CDDO-3-P-Im
CDDO-2P-Imidazolide | [Molecular Formula]
C39H46N4O3 | [MDL Number]
MFCD32693893 | [MOL File]
1883650-96-1.mol | [Molecular Weight]
618.81 |
| Chemical Properties | Back Directory | [Boiling point ]
766.1±70.0 °C(Predicted) | [density ]
1.25±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: 250 mg/mL (404.00 mM) | [form ]
Solid | [pka]
1.60±0.19(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
CDDO-2P-Im is an analogue of CDDO-Imidazolide with chemopreventive effect. CDDO-2P-Im can reduce the size and the severity of the lung tumors in mouse lung cancer model[1]. | [in vivo]
CDDO-2P-Im is more stable than CDDO-Im in pharmacokinetic studies[1].
CDDO-2P-Im significantly elevates heme oxygenase-1 (HO-1) and quinone reductase (NQO1) mRNA and protein levels in various mouse tissues in vivo[1].
CDDO-2P-Im (50-200 mg/kg; diet; for 16 weeks) decreases the number, the size and the severity of tumors in A/J mice[1].
| Animal Model: | Seven week-old female A/J mice[1] | | Dosage: | 50 mg/kg, 200 mg/kg | | Administration: | Diet; for 16 weeks | | Result: | Decreased the number, the size and the severity of tumors. |
| [References]
[1] Cao M , et al. Novel synthetic pyridyl analogues of CDDO-Imidazolide are useful new tools in cancer prevention. Pharmacol Res. 2015 Oct;100:135-47. DOI:10.1016/j.phrs.2015.07.024 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
|